'Herzuma', which is biosimilar product of ‘Herceptin’ for the breast cancer treatment has permitted
Ministry of food and drug safety announced that on Jan 15, they permitted the biosimilar product 'Herzuma' which Celltrion had developed. Herzuma is first biosimilar product in the world that has anti-cancer effect.
It is biosimilar product of the breast cancer treatment, '...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
